BRIEF — NICE recommends Fotivda in advanced RCC

UK-based EUSA Pharma has received good news on Fotivda (tivozanib), the product that it holds exclusive commercialization rights to in renal cell carcinoma (RCC) in Europe and other ex-North America territories.

The UK’s National Institute for Health and Care Excellence (NICE) has published a final appraisal determination (FAD) recommending Fotivda as a first-line treatment option for advanced RCC in line with its licensed indication. It will now become available on the National Health Service in England and Wales.

Fotivda was licensed by the European Commission in August 2017 and is an oral, once-daily, potent selective vascular endothelial growth factor receptor tyrosine kinase inhibitor. In North America, rights to the drug are retained by US biotech AVEO Oncology (Nasdaq: AVEO).